- Home
- BLE vs CELC Comparison
BLE vs CELC Comparison
Compare BLE & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLE
- CELC
- Stock Information
- Founded
- BLE 2002
- CELC 2011
- Country
- BLE United States
- CELC United States
- Employees
- BLE N/A
- CELC N/A
- Industry
- BLE Finance/Investors Services
- CELC Medical Specialities
- Sector
- BLE Finance
- CELC Health Care
- Exchange
- BLE Nasdaq
- CELC Nasdaq
- Market Cap
- BLE 475.4M
- CELC 440.0M
- IPO Year
- BLE N/A
- CELC 2017
- Fundamental
- Price
- BLE $10.42
- CELC $54.91
- Analyst Decision
- BLE
- CELC Strong Buy
- Analyst Count
- BLE 0
- CELC 5
- Target Price
- BLE N/A
- CELC $53.60
- AVG Volume (30 Days)
- BLE 108.3K
- CELC 854.3K
- Earning Date
- BLE 01-01-0001
- CELC 08-14-2025
- Dividend Yield
- BLE 4.46%
- CELC N/A
- EPS Growth
- BLE N/A
- CELC N/A
- EPS
- BLE 0.01
- CELC N/A
- Revenue
- BLE N/A
- CELC N/A
- Revenue This Year
- BLE N/A
- CELC N/A
- Revenue Next Year
- BLE N/A
- CELC N/A
- P/E Ratio
- BLE $1,082.00
- CELC N/A
- Revenue Growth
- BLE N/A
- CELC N/A
- 52 Week Low
- BLE $8.77
- CELC $7.58
- 52 Week High
- BLE $10.95
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- BLE 80.58
- CELC 58.98
- Support Level
- BLE $9.80
- CELC $50.44
- Resistance Level
- BLE $9.96
- CELC $63.06
- Average True Range (ATR)
- BLE 0.07
- CELC 3.20
- MACD
- BLE 0.06
- CELC -0.73
- Stochastic Oscillator
- BLE 96.88
- CELC 43.13
About BLE BlackRock Municipal Income Trust II
Blackrock Municipal Income Trust II is a perpetual closed-end municipal bond fund. Its objective is to provide high current income exempt from regular U.S. federal income tax consistent with the preservation of capital. The Fund seeks to achieve its investment objective by investing at least 80% of its assets in municipal obligations that pay interest that is exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax).
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.